Dr. Benjamin Ebert is the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, Chair of Medical Oncology at the Dana-Farber Cancer Institute, a Howard Hughes Medical Institute Investigator, and an Institute Member of the Broad Institute.
The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies and its non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS) and clonal hematopoiesis. The Ebert laboratory demonstrated that lenalidomide, a derivative of thalidomide, binds the CRL4-CRBN E3 ubiquitin ligase and induces degradation of specific substrates. Subsequent research from the Ebert laboratory has examined the potential of thalidomide analogs to induce degradation of a broad array of zinc finger transcription factors and other proteins, and to identify novel mechanisms of drug-induced protein degradation.
Dr. Ebert is an elected member of the National Academy of Medicine, the American Society for Clinical Investigation and the Association of American Physicians. He served as President of the American Society for Clinical Investigation. His awards include the Till and McCollough Award from the International Society of Experimental Hematopoiesis, the William Dameshek Prize from the American Society of Hematology, the Meyenburg Prize, and mentoring and teaching awards from Harvard Medical School.
Dr. Ebert received a bachelor's degree from Williams College and a doctorate from Oxford University as a Rhodes Scholar where he worked with Peter Ratcliffe, who was subsequently awarded the Nobel Prize in Medicine. He completed an M.D. from Harvard Medical School, a residency in internal medicine at Massachusetts General Hospital, and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. He was on the faculty of Brigham and Women’s Hospital for 10 years before returning to the Dana-Farber.